Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy.

• Main Authors: Imjai Chitapanarux, Vicharn Lorvidhaya, Pimkhuan Kamnerdsupaphon, Ekkasit Tharavichitkul, Hongsin Trakultivakorn, Areewan Somwangprasert, Somsak Sumitsawan, Songphol Srisukho, Keerati Watcharachan, Vimol Sukthomya
• 格式: 雜誌
• 出版: 2018
• 主題: Biochemistry, Genetics and Molecular Biology; Medicine
• 在線閱讀: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33745515798&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/61519
• 機構: Chiang Mai University

BACKGROUND: In clinical studies of both heavily and minimally pretreated patients with advanced breast cancer, the combination of Gemcitabine plus cisplatin (GC), given in a variety of schedules and doses, has demonstrated moderate safety and efficacy in both heavily and minimally pretreated advance...